Testing bronchodilator responsiveness
Eur Respir J
.
2019 Dec 4;54(6):1902104.
doi: 10.1183/13993003.02104-2019.
Print 2019 Dec.
Authors
Christer Janson
1
2
,
Andrei Malinovschi
3
,
Andre F S Amaral
2
,
Simone Accordini
4
,
Jean Bousquet
5
6
7
,
A Sonia Buist
8
,
Judith Garcia-Aymerich
9
10
11
,
Louisa Gnatiuc
12
,
Wan Tan
13
,
Kjell Torén
14
,
Torsten Zuberbier
7
,
Peter Burney
2
;
all the authors
Affiliations
1
Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
2
Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK.
3
Dept of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden.
4
Unit of Epidemiology and Medical Statistics, Dept of Diagnostics and Public Health, University of Verona, Verona, Italy.
5
Fondation FMC VIA-LR, Montpellier, France.
6
Euforea, Brussels, Belgium.
7
Allergy Centre Charité, Dept of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.
8
Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA.
9
ISGlobal, Barcelona, Spain.
10
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
11
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
12
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Dept of Population Health, University of Oxford, Oxford, UK.
13
Centre for Heart Lung Innovation (Tan, Sin), University of British Columbia, St. Paul's Hospital Vancouver, Vancouver, BC, Canada.
14
Dept of Occupational and Environmental Medicine, University of Gothenburg, Gothenburg, Sweden.
PMID:
31801819
DOI:
10.1183/13993003.02104-2019
No abstract available
Publication types
Letter
Comment
MeSH terms
Asthma*
Bronchodilator Agents
Forced Expiratory Volume / drug effects
Humans
Pulmonary Disease, Chronic Obstructive*
Substances
Bronchodilator Agents
Grants and funding
G0901214/MRC_/Medical Research Council/United Kingdom